

Supporting Information

Synthesis and Biological Evaluation of the Ascidian Blood-Pigment Halocyamine A

Hugo K. H. Fong,^a Jean Michel Brunel,^b Arlette Longeon,^c Marie-Lise Bourguet-Kondracki,^c
David Barker,^a and Brent R. Copp^{*a}

^aSchool of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland 1010, New Zealand

^bCentre de Recherche en Cancérologie de Marseille (CRCM), CNRS, UMR7258, Institut Paoli Calmettes, Aix-Marseille Université, UM 105, Inserm, U1068, F-13009 Marseille, France

^cLaboratoire Molécules de Communication et Adaptation des Micro-organismes, UMR 7245 CNRS, Muséum National d'Histoire Naturelle, 57 rue Cuvier (C.P. 54), 75005 Paris, France.

*Corresponding author E-mail: b.copp@auckland.ac.nz

Contents:

Table S1. NMR data of isolated halocyamine A (1) and synthetic halocyamine A HCl salt (1).	
.....	S2
¹ H and ¹³ C NMR Spectra.....	S3–S44

Table S1. NMR data of isolated halocytamine A (1) and synthetic halocytamine A HCl salt (1) in DMSO-*d*₆.


Atom No.	¹ H [δ, mult., <i>J</i> (Hz)]		¹³ C (δ)	
	Isolated (1) ¹	Synthetic (1)	Isolated (1) ¹	Synthetic (1)
1	Not observed	Not observed (8.37 [3H, br s]) [*]	-	-
2	3.84 (1H, t, 5.0)	3.61 (1H, br s)	53.10	53.8
3	3.03 (1H, dd, 15.5, 5.0), 2.93 (1H, dd, 15.5, 7.5)	2.91–2.89 (1H, m), 2.73 (1H, dd, 14.3, 7.5)	29.62	30.5
4	-	-	132.88	133.4
5	-	-	-	-
6	7.65 (1H, s)	7.60 (1H, s)	135.13	135.1
7	Not observed	Not observed	-	-
8	6.90 (1H, s)	6.86 (1H, s)	116.37	Not observed (118.2) [*]
9	-	-	170.27	171.6
10	8.84 (1H, br d, 6.8)	8.40 (1H, br s)	-	-
11	4.43 (1H, m)	4.44 (1H, br s)	54.94	54.5
12	2.98 [#] , 2.65 (1H, dd, 14.0, 10.5),	2.95 (1H, dd, 14.0, 4.1), 2.66 (1H, dd, 14.0, 9.6)	36.46	36.7
13	-	-	128.42	128.5
14	6.81 (1H, d, 1.8)	6.64 (1H, d, 1.5)	116.76	116.6
15	-	-	145.03	144.9
16	-	-	143.72	143.7
17	6.59 (1H, d, 8.0)	6.59 (1H, d, 8.0)	115.24	115.3
18	6.47 (1H, dd, 8.0, 1.8)	6.45 (1H, dd, 8.0, 1.5)	119.47	119.9
19	-	-	171.96	171.9
20	9.16 (1H, br t, 6.5)	8.88 (1H, br s)	-	-
21	3.97 (2H, d, 5.5)	3.99 (1H, dd, 16.6, 5.8), 3.93 (1H, dd, 16.6, 5.8)	42.72	42.6
22	-	-	167.39	167.5
23	9.04 (1H, d, 10.5)	9.08 (1H, d, 10.0)	-	-
24	6.69 (1H, t, 9.5)	6.67 (1H, dd, 10.0, 9.7)	118.39	118.6
25	5.92 (1H, d, 9.5)	5.92 (1H, d, 9.7)	102.10	102.2
26	-	-	109.59	109.7
27	7.73 (1H, s)	7.72 (1H, s)	124.72	124.9
28	11.85 (1H, s)	11.51 (1H, br s)	-	-
28a	-	-	136.43	136.4
29	7.61 (1H, d, 2.0)	7.58 (1H, d, 1.6)	114.12	114.1
30	-	-	114.24	114.3
31	7.15 (1H, dd, 8.5, 2.0)	7.16 (1H, dd, 8.3, 1.6)	121.73	121.9
32	7.55 (1H, d, 8.5)	7.56 (1H, d, 8.3)	119.90	120.1
32a	-	-	125.59	125.7

^{*}signals observed for synthetic halocytamine A TFA salt in DMSO-*d*₆.


[#]3.00 ppm, dd, *J* = 14.0 and 5.6 Hz, in CH₃OD

Reference


(1) K. Azumi, H. Yokosawa, S. Ishii, *Biochemistry* 1990, **29**, 159–165.



¹H NMR (CDCl₃, 500 MHz) of Fmoc-His(Trt)-DOPA(TBDMS)₂-Gly-OH (4).



^{13}C NMR (CDCl_3 , 125 MHz) of Fmoc-His(Trt)-DOPA(TBDMS)₂-Gly-OH (4).




^1H NMR (CDCl_3 , 500 MHz) of Fmoc-His(Trt)-DOPA(TBDMS) $_2$ -Gly-NH $_2$ (3).


Current Data Parameters
NAME HF8-34_27-30
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date_ 20160715
Time 7.29
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 32768
SOLVENT CDCl3
NS 32
DS 0
SWE 10000.000 Hz
FIDRES 0.305176 Hz
AQ 1.6384000 sec
RG 175.28
DW 50.000 usec
DE 6.50 usec
TE 300.0 K
D1 0.10000000 sec
TD0 1

===== CHANNEL F1 =====
SFO1 500.1925007 MHz
NUC1 1H
P1 10.00 usec
PLW1 21.00000000 W


F2 - Processing parameters
SI 16384
SF 500.1900129 MHz
WDW EM
SSB 0
LB 0.10 Hz
GB 0
PC 0.80









^1H NMR (CDCl_3 , 500 MHz) of a mixture of (*Z*)-but-1-en-3-yne-1,4-diyl dibenzene (5) and (*E*)-but-1-en-3-yne-1,4-diyl dibenzene (6).




^{13}C NMR (CDCl_3 , 125 MHz) of a mixture of (*Z*)-but-1-en-3-yne-1,4-diyl dibenzene (5) and (*E*)-but-1-en-3-yne-1,4-diyl dibenzene (6).




^1H NMR (CDCl_3 , 500 MHz) of (Z)-(9H-fluoren-9-yl)methyl (2-oxo-2-(styrylamino)ethyl)carbamate (**10**).




^{13}C NMR (CDCl_3 , 125 MHz) of (Z)-(9H-fluoren-9-yl)methyl (2-oxo-2-(styrylamino)ethyl)carbamate (**10**).





^1H NMR (CDCl_3 , 400 MHz) of *tert*-butyl (Z)-(2-oxo-2-(styrylamino)ethyl)carbamate (**12**).




^{13}C NMR (CDCl_3 , 100 MHz) of *tert*-butyl (Z)-(2-oxo-2-(styrylamino)ethyl)carbamate (**12**).



^1H NMR (CDCl_3 , 500 MHz) of (Z)-2-amino-N-styrylacetamide (**8**).



^{13}C NMR (CDCl_3 , 125 MHz) of (Z)-2-amino-N-styrylacetylamide (**8**).



^1H NMR (CDCl_3 , 500 MHz) of Fmoc-His(Trt)-DOPA(TBDMS) $_2$ -OH (7).

```


Current Data Parameters
NAME      HP7-139
EXPNO     2
PROCNO    1


F2 - Acquisition Parameters
Date_     20160417
Time      20.13
INSTRUM   spect
PROBHD    5 mm F4BBO BB/
PULPROG   zg30
TD        32768
SOLVENT   CDCl3
NS        16
DS        0
SWH       10000.000 Hz
FIDRES    0.305176 Hz
AQ        1.6384000 sec
RG        27.23
BW        50.000 usec
DE        6.50 usec
TE        300.0 K
D1        0.10000000 sec
TDC        1

===== CHANNEL f1 =====
SFO1      500.1925007 MHz
NUC1      1H
P1        10.00 usec
PLW1      21.00000000 W


F2 - Processing parameters
SI        16384
SF        500.1900193 MHz
WDW       EM
SSB       0
LB        0.10 Hz
GB        0
PC        0.80

```







^{13}C NMR (CDCl_3 , 125 MHz) of Fmoc-His(Trt)-DOPA(TBDMS)₂-OH (7).




^1H NMR (CDCl_3 , 500 MHz) of (9*H*-fluoren-9-yl)methyl ((*S*)-1-(((*S*)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-oxo-1-((2-oxo-2-(((*Z*)-styryl)amino)ethyl)amino)propan-2-yl)amino)-1-oxo-3-(1-trityl-1*H*-imidazol-4-yl)propan-2-yl)carbamate (**13**).




¹³C NMR (CDCl₃, 125 MHz) of (9*H*-fluoren-9-yl)methyl ((*S*)-1-(((*S*)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-oxo-1-((2-oxo-2-(((*Z*)-styryl)amino)ethyl)amino)propan-2-yl)amino)-1-oxo-3-(1-trityl-1*H*-imidazol-4-yl)propan-2-yl)carbamate (**13**).




^1H NMR (CDCl_3 , 400 MHz) of (S)-2-amino-N-((S)-3-(3,4-bis((tert-butyl dimethylsilyl)oxy)phenyl)-1-oxo-1-((2-oxo-2-(((Z)-styryl)amino)ethyl)amino)propan-2-yl)-3-(1-trityl-1H-imidazol-4-yl)propanamide (**14**).




^{13}C NMR (CDCl_3 , 125 MHz) of (S)-2-amino-N-((S)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-oxo-1-(((*Z*)-styryl)amino)ethyl)amino)propan-2-yl)-3-(1-trityl-1*H*-imidazol-4-yl)propanamide (**14**).




¹H NMR (CD₃OD, 500 MHz) of (S)-2-amino-N-((S)-3-(3,4-dihydroxyphenyl)-1-oxo-1-((2-oxo-2-(((Z)-styryl)amino)ethyl)amino)propan-2-yl)-3-(1-trityl-1H-imidazol-4-yl)propanamide (15).




¹³C NMR (CD₃OD, 125 MHz) of (S)-2-amino-N-((S)-3-(3,4-dihydroxyphenyl)-1-oxo-1-((2-oxo-2-(((Z)-styryl)amino)ethyl)amino)propan-2-yl)-3-(1-trityl-1H-imidazol-4-yl)propanamide (**15**).




^1H NMR (DMSO- d_6 , 500 MHz) of 4-((S)-2-ammonio-3-(((S)-3-(3,4-dihydroxyphenyl)-1-oxo-1-((2-oxo-2-(((Z)-styryl)amino)ethyl)amino)propan-2-yl)amino)-3-oxopropyl)-1H-imidazol-3-ium chloride (2).




^{13}C NMR (DMSO- d_6 , 125 MHz) of 4-((S)-2-ammonio-3-(((S)-3-(3,4-dihydroxyphenyl)-1-oxo-1-((2-oxo-2-(((Z)-styryl)amino)ethyl)amino)propan-2-yl)amino)-3-oxopropyl)-1H-imidazol-3-ium chloride (2).




¹H NMR (CDCl₃, 400 MHz) of *tert*-Butyl-6-bromo-3-iodo-1*H*-indole-1-carboxylate (**19**).




^1H NMR (CDCl_3 , 400 MHz) of *tert*-Butyl-6-bromo-3-iodo-1*H*-indole-1-carboxylate (**19**)




¹H NMR (CDCl₃, 400 MHz) of *tert*-butyl 6-bromo-3-((trimethylsilyl)ethynyl)-1*H*-indole-1-carboxylate (**20**).




^{13}C NMR (CDCl_3 , 100 MHz) of *tert*-butyl 6-bromo-3-((trimethylsilyl)ethynyl)-1*H*-indole-1-carboxylate (**20**).




^1H NMR (CDCl_3 , 400 MHz) of *tert*-butyl 6-bromo-3-ethynyl-1*H*-indole-1-carboxylate (**17**).




^{13}C NMR (CDCl_3 , 100 MHz) of *tert*-butyl 6-bromo-3-ethynyl-1*H*-indole-1-carboxylate (**17**).




¹H NMR (CDCl₃, 400 MHz) of *tert*-butyl (Z)-3-(2-(2-aminoacetamido)vinyl)-6-bromo-1*H*-indole-1-carboxylate (**21**).




¹³C NMR (CDCl₃, 100 MHz) of *tert*-butyl (Z)-3-(2-(2-aminoacetamido)vinyl)-6-bromo-1*H*-indole-1-carboxylate (**21**).




¹H NMR (CDCl₃, 400 MHz) of (*E*)-di-*tert*-butyl 3,3'-(but-1-en-3-yne-1,4-diyl)bis(6-bromo-1*H*-indole-1-carboxylate) (22).




^{13}C NMR (CDCl_3 , 100 MHz) of (*E*)-di-*tert*-butyl 3,3'-(but-1-en-3-yne-1,4-diyl)bis(6-bromo-1*H*-indole-1-carboxylate) (22).




^1H NMR (DMSO- d_6 , 400 MHz) of (Z)-2-amino-N-(2-(6-bromo-1H-indol-3-yl)vinyl)acetamide (**16**).




^{13}C NMR (DMSO- d_6 , 100 MHz) of (Z)-2-amino-N-(2-(6-bromo-1H-indol-3-yl)vinyl)acetamide (**16**).



^1H NMR (CDCl_3 , 500 MHz) of (9*H*-fluoren-9-yl)methyl ((*S*)-1-(((*S*)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-((2-(((*Z*)-2-(6-bromo-1*H*-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-1-oxopropan-2-yl)amino)-1-oxo-3-(1-trityl-1*H*-imidazol-4-yl)propan-2-yl)carbamate (**23**).





```

Current Data Parameters
NAME: HF6-153_35-40
EXPNO: 2
PROCNO: 1


F2 - Acquisition Parameters
Date_: 20151031
Time: 14.54
INSTRUM: spect
PROBHD: 5 mm F400 BBO
PULPROG: zgpg
TD: 65536
SOLVENT: CDCl3
NS: 2302
DS: 0
SWH: 29761.904 Hz
FIDRES: 0.454131 Hz
AQ: 1.1010048 sec
RG: 719.15
DW: 16.800 usec
DE: 6.50 usec
TE: 300.0 K
D1: 0.63058811 sec
D11: 0.03000000 sec
TD0: 1

===== CHANNEL f1 =====
SFO1: 125.7868349 MHz
NUC1: 13C
P1: 5.56 usec
PLW1: 83.0000000 W



===== CHANNEL f2 =====
SFO2: 500.1318000 MHz
NUC2: 1H
PCPDG[2]: waltz16
PCPD2: 80.00 usec
PLW2: 21.0000000 W
PLW12: 0.32813001 W
PLW13: 0.20999999 W

F2 - Processing parameters
SI: 32768
SF: 125.7728592 MHz
WDW: EM
SSB: 0
LB: 2.00 Hz
GB: 0
PC: 0.80


```



¹³C NMR (CDCl₃, 125 MHz) of (9*H*-fluoren-9-yl)methyl ((*S*)-1-(((*S*)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-((2-(((*Z*)-2-(6-bromo-1*H*-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-1-oxopropan-2-yl)amino)-1-oxo-3-(1-trityl-1*H*-imidazol-4-yl)propan-2-yl)carbamate (**23**).



^1H NMR (CDCl_3 , 500 MHz) of (S)-2-amino-N-((S)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-((2-(((Z)-2-(6-bromo-1*H*-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-1-oxopropan-2-yl)-3-(1-trityl-1*H*-imidazol-4-yl)propanamide (**24**).




Current Data Parameters
NAME EF6-162_6-10
EXPNO 5
PROCNO 1

F2 - Acquisition Parameters
Date_ 20151103
Time 6.08
INSTRUM spect
PROBHD 5 mm PAB30 BB/
PULPROG zgpg
ID 65536
SOLVENT CDCl3
NS 2251
DS 0
SWH 29761.904 Hz
FIDRES 0.454131 Hz
AQ 1.1210048 sec
RG 749.15
DW 16.800 usec
DE 6.50 usec
TE 300.0 K
D1 0.63008811 sec
D11 0.03000000 sec
TD0 1



===== CHANNEL f1 =====
SFO1 125.7668349 MHz
NUC1 13C
P1 5.56 usec
PLW1 83.00000000 W

===== CHANNEL f2 =====
SFO2 500.1318000 MHz
NUC2 1H
CFDPRG12 waltz16
PCPD2 80.00 usec
PLW2 21.00000000 W
PLW12 0.32813001 W
PLW13 0.209999999 W


F2 - Processing parameters
ST 32768
SF 125.7728755 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
PC 0.80




¹³C NMR (CDCl₃, 125 MHz) of (S)-2-amino-N-((S)-3-(3,4-bis((tert-butyl)dimethylsilyl)oxy)phenyl)-1-(((Z)-2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-1-oxopropan-2-yl)-3-(1-trityl-1H-imidazol-4-yl)propanamide (**24**).




^1H NMR (CD_3OD , 500 MHz) of (S)-2-amino-N-((S)-1-((2-((Z)-2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-yl)-3-(1-phenyl-1H-imidazol-4-yl)propanamide (**25**).



^{13}C NMR (CD_3OD , 125 MHz) of (S)-2-amino-N-((S)-1-((2-(((Z)-2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-yl)-3-(1-trityl-1H-imidazol-4-yl)propanamide (25).







Current Data Parameters
NAME HF8-28(2)_10-43
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160702
Time 11.07
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 32
DS 0
SWH 10000.000 Hz
FIDRES 0.305176 Hz
AQ 1.6384000 sec
RG 175.28
DW 50.000 usec
DE 6.50 usec
TE 300.0 K
D1 0.1000000 sec
TDC 1

----- CHANNEL f1 -----
SFO1 500.1925007 MHz
NUC1 1H
P1 10.00 usec
PLW1 21.00000000 W

F2 - Processing parameters
S1 16384
SF 500.1900057 MHz
WDW EM
SSB 0
LB 0.10 Hz
GB 0
PC 0.80





^{13}C NMR (DMSO- d_6 , 125 MHz) of halocytamine A dihydrochloride salt (**1**).

